On 21 August 2019, orphan designation EU/3/19/2200 was granted by the European Commission to Dr Sebastian Canisius, Germany, for clofazimine for the treatment of nontuberculous mycobacterial lung disease.
The sponsorship was transferred to Aclira Consulting GmbH, Germany in January 2021.
|Disease / condition||
Treatment of nontuberculous mycobacterial lung disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.